Immune-mediated mechanisms of atherosclerosis and implications for the clinic
Meritxell Nus¹ and Ziad Mallat¹

¹Division of Cardiovascular Medicine, Dept. of Medicine, University of Cambridge, United Kingdom.

Abstract
Introduction: A large body of evidence supports the inflammatory hypothesis of atherosclerosis. And both innate and adaptive immune responses play important roles in all disease stages.
Areas covered: Here, we review our understanding of the role of the immune response in atherosclerosis, focusing on the pathways currently amenable to therapeutic modulation. We also discuss the advantages or undesirable effects that may be foreseen from targeting the immune response in patients at high cardiovascular risk, suggesting new avenues for research.
Expert commentary: There is an extraordinary opportunity to directly test the inflammatory hypothesis of atherosclerosis in the clinic using currently available therapeutics. However, a more balanced interpretation of the experimental and translational data is needed, which may help address and identify in more detail the appropriate settings where an immune pathway can be targeted with minimal risk.

Keywords: Innate immune response, adaptive immune response, atherosclerosis, anti-inflammatory therapies.
Abbreviations

Cardiovascular (CV)
Low-density lipoproteins (LDL)
Pathogen associated molecular patterns (PAMPs)
Damage-associated molecular patterns (DAMPs)
Pattern recognition receptors (PRR)
Dendritic cells (DC)
Immunoglobulins (Ig)
T cell receptors (TCR)
Oxidized-LDL (oxLDL)
High-sensitivity C-reactive protein (hsCRP)
Endothelial cells (EC)
Smooth muscle cells (SMC)
IL1-receptor type-1 (IL1R1)
Mitochondrial uncoupling protein (UCP)
IL1R accessory protein (IL1RAP)
myeloid differentiation factor 88 (MyD88)
c-Jun N terminal kinases (JNKs)
Extracellular signal-regulated kinases (ERKs)
Mitogen-activated protein kinases (MAPKs)
IL1R antagonist (IL1Ra)
Macrophage colony-stimulating factor (M-CSF)
Bone marrow transplantation (BMT)
Acute coronary syndromes (ACS)
Coronary artery disease (CAD)
Oxidized phospholipids (OxPL)
Rheumatoid arthritis (RA)
Subcutaneous (s.c.)
Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
Methotrexate (MTX)
5-aminoimidazole-4-carboxamide ribonucleotide (AICAR)
Lectin-like oxidised LDL receptor -1 (LOX1)
Cardiovascular Inflammation Reduction Trial (CIRT)
Acute phase response (APR)
Suppressor of cytokine signaling 3 (SOCS3)
Lipoprotein a (Lp(a))
Platelet-activator factor factor (PAF)
Lysophosphatidylcholine (LysoPC)
Stabilization of Atherosclerosis Plaque by Darapladib Initiation of Therapy (STABILITY)
Stabilization of Plaques Using Darapladib-Thrombolysis in MI 52 Trial (SOLID-TIMI 52)
Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression (FRANCIS)
Antigen presenting cells (APC)
Major histocompatibility complex class II molecule (MHCII)
T regulatory (Tregs)
Retinoic acid orphan receptors (ROR)
Naturally occurring Tregs (nTregs)
Adaptive/induced Treg cells (iTreg)
Introduction

Atherosclerosis is responsible for most ischemic cardiovascular (CV) diseases and is a leading cause of death and morbidity worldwide. Atherosclerosis is a complex arterial pathology with multiple genetic and environmental risk factors, initiated in response to trapping of low-density lipoproteins (LDL) in the intima and their acquisition of immunogenic properties through both enzymatic and non-enzymatic (oxidative) modifications. The subsequent immune response involves interactions between many vascular and circulating cells and mediators, and frequently leads to a chronic inflammatory state due at least in part to defects in counter-regulatory mechanisms. Broad evidence supports the inflammatory theory of atherosclerosis, and immune cells have been shown to participate in all stages of the disease from its initiation to progression and plaque rupture or erosion.

An innate immune response is initiated by the recognition of signature molecules that the organism considers as carrying a danger. Those molecules can be of microbial origin (i.e. pathogen associated molecular patterns or PAMPs) or self-molecules that are only secreted or exposed to the immune system in case of cell injury or death (i.e. damage-associated molecular patterns or DAMPs). Following recognition through germline encoded receptors (called pattern recognition receptors PRR) expressed in innate immune cells (e.g., monocytes/macrophages, neutrophils, dendritic cells (DC), NK cells, B1 cells), PAMPs and DAMPs activate protective responses leading to the killing of the microbe or the clean-up and repair of dead tissue.

The adaptive immune response is induced by other types of molecules (i.e. antigens), which are recognized by highly selected, clonally developed and specific antigen receptors, e.g., immunoglobulins (Ig) in B cells, and T cell receptors (TCR) in T cells. Antigen recognition in combination with additional signals delivered by co-stimulatory molecules and soluble mediators, lead to the proliferation and differentiation of lymphocytes into antigen-specific effector cells helping to eradicate the aggression.

When the stimuli are persistent (as it may be the case for oxidized-LDL (oxLDL) or cholesterol crystals in atherosclerosis), continued innate and adaptive immune activation will promote chronic inflammation, damaging the tissues and leading to disease. Patients with elevated inflammatory biomarkers such as high-sensitivity C-reactive protein (hsCRP) have increased CV risk, and recent work directly implicates both the innate and adaptive immune pathways in the development and complications of human atherosclerosis. Yet, it remains unknown whether targeted inhibition of immune responses will reduce CV event rates. In the present review we will discuss the role of selective innate and adaptive immune responses in atherosclerosis. We will focus on currently targeted pathways, and pathways that are susceptible to be targeted by available drugs; we will explain how this basic and experimental knowledge may be translated to the clinic with the aim to develop better therapies and reduce disease burden.

Therapies targeting the innate immune response

IL1 pathway
Pathophysiological pathway: The IL1 family of cytokines comprises 11 proteins, encoded by different genes, which initiate and regulate inflammatory processes [1]. The founding members are IL1α and IL1β, which exert the most potent pro-inflammatory effects. They are mainly produced by monocytes and macrophages but also in lower amounts by neutrophils, keratinocytes, epithelial and endothelial cells (EC), lymphocytes, smooth muscle cells (SMC) and fibroblasts. Despite IL1α and IL1β only showing a 24% amino acid sequence homology, they display largely identical biological functions. They both bind to the same surface receptor, called IL1-receptor type-I (IL1R1), which is ubiquitously expressed.

IL1α is synthesized as a 33kDa precursor peptide (proIL1α) that can be cleaved by the activation of the calcium-dependent membrane-associated cysteine protease calpain to produce an active 17kDa peptide with full biological activity [2]. IL1α activation depends on the cell type and IL1α is up to 50 fold times more active than proIL1α due to increased IL1R1 affinity for IL1α [3]. In some cells, there is also an IL1R2 that binds to proIL1α impairing calpain-mediated cleavage. However, following inflammasome activation, caspase-1 specifically cleaves IL1R2 and restores full IL1α activity [3]. An inflammasome-independent mechanism of IL1α production was also described recently. Fatty acids selectively stimulated the release of IL1α in macrophages by a mechanism involving the mitochondrial uncoupling protein (UCP)2 [4]. Interestingly, UCP2 in turn may promote inflammasome-dependent caspase-1 activation and IL1β production through modulation of de novo fatty acid synthesis [5].

IL1β is synthesized as a biologically inactive 31kDa precursor peptide (proIL1β) (extensively reviewed in [6]). Pro-IL1β must be cleaved, mainly by caspase-1, to generate an active 17kDa peptide and to exert its function. Caspase-1 is regulated by a multiprotein oligomer, known as inflammasome, which acts as a sensor of the innate immune response. Activation of NLRP3 inflammasome can be induced by particulate ligands (i.e. cholesterol crystals in atherosclerosis) [7] or soluble ligands (i.e. oxidized LDL) converted intracellularly into crystals [8]. IL1α and/or β binding to IL1R1 induces the recruitment of a second receptor chain called IL1R accessory protein (IL1RAP) to the intracellular domain of IL1R1. The IL1(α or β)-IL1R1-IL1RAP ternary complex recruits several intracellular adaptor proteins to trigger a signaling cascade that activates pro-inflammatory transcription factors (reviewed in [1]). As a result, IL1 signaling leads to the activation of several target genes like pro-inflammatory molecules (e.g.. TNFα, IL6, IL8, etc.), EC adhesion molecules, and macrophage colony-stimulating factor (CSF1), etc.

IL1R antagonist (IL1RN) is a major natural competitive inhibitor of the binding of IL1 to its receptor. Despite the same affinity of IL1 and IL1RN for IL1R1, there is a need for a large molar excess of IL1RN (100 to 1000-fold) to block IL1 activity. IL1R antagonist (IL1RN) is a major natural competitive inhibitor of the binding of IL1 to its receptor. Despite the same affinity of IL1 and IL1RN for IL1R1, there is a need for a large molar excess of IL1RN (100 to 1000-fold) to block IL1 activity [6].

Experimental evidence: A role for IL1 has been described in both early [9–11] and advanced [12,13] atherosclerosis. At the early stages of fatty streaks formation, exogenous administration [9] of IL1RN or its genetic overexpression [10,11] decreases atherosclerotic plaque formation in murine models. Apoe−/− mice lacking IL1RN develop a severe form of aortic inflammation with massive macrophage infiltration in the adventitia, macrophage lipid accumulation, and
marked destruction of the aortic lamina [11]. This effect is not observed in Il1rn−/− mice on Apoe−/− background, suggesting that the lack of IL1RN is not sufficient to promote arteritis in normo-cholesterolemic animals.

In contrast, the role of IL1 signaling in more advanced stages of atherosclerosis remains debated. For example, plaque size did not differ between Apoe−/−/Il1r1+/− and Apoe−/−/Il1r1−/− mice but the latter developed more unstable-appearing plaques, as revealed by reduced collagen and SMC accumulation and increased occurrence of intraplaque haemorrhage [12]. Thus, animal models of atherosclerosis have shown a dual role for IL1, pro-atherogenic at early stages, but potentially protective (enhancing plaque stability) at advanced stages. IL1R1 and IL1RN respectively mediate and inhibit both IL1α and IL1β, but whether the 2 forms of IL1 exhibit similar or contrasting roles in atherosclerosis is still under intense investigation.

C57Bl6 Il1b−/− mice showed decreased atherosclerotic plaques after high fat diet. The same atheroprotective effect was observed in Il1a−/− despite increased non-HDL-cholesterol levels. Bone marrow transplantation (BMT) from Il1a−/− mice into WT mice did not alter lipoprotein levels but still decreased atherosclerotic plaque formation. However, BMT from Il1b−/− did not affect plaque size [14]. Thus only IL1α secretion from bone marrow-derived cells appears to be atherogenic. This conclusion is supported by recent data obtained in Ldlr−/− mice [4]. Nevertheless, treatment with monoclonal antibodies against IL1β (XOMA 052) in atherosclerotic mice, significantly decreased atherosclerotic plaque formation associated with reduced non-HDL/HDL ratio, plaque lipid content and macrophage infiltration [15].

Translational studies: In the late 80’s several in vitro experiments using human cell cultures suggested a potential role of IL1β in atherosclerosis. In vitro IL1β regulates SMC mitogenesis [16], induces leukocyte adhesion to the endothelium [17], modulates LDL oxidation [18], and promotes vascular permeability [19]. Both IL1β and IL1α were detected in human atherosclerotic plaques [20], IL1β being mostly released by macrophages and active IL1α by SMC [21,22].

IL1 is almost undetectable in blood using routine methods, so only a very few epidemiological studies are available on the relationship between circulating IL1 and CV risk [23]. Patients with greater atherosclerotic burden [24,25] presented increased IL1β levels, which were associated with less favorable prognosis after acute coronary syndromes (ACS) [26,27].

Two polymorphisms have been described for the Il1B gene, the frequent variant Il1B*1 (a single transition from C-T in position -511) and the rare variant Il1B*2 (a single transition C-T in exon 5 in position +3953). Only one study found an association between specific combinations of these polymorphisms and the risk of developing coronary artery disease (CAD) in individuals with increased oxidized phospholipids (OxPL)/apoB ratio [28]. The polymorphic region within intron 2 of the IL1 receptor antagonist gene (Il1rn) contains a variable number of tandem repeats of 86 base pairs, with Il1rn*1 representing four repeats of the 86 bp in tandem, Il1rn*2 having two repeats, and Il1rn*3 containing five repeats [29]. Carriers of the Il1rn*2 polymorphism release more IL1RN, which was related to reduced atherosclerotic plaque size in some European populations [30,31], but not in others [32]. Recently, another two uncorrelated variants rs6743376 and rs1542176 located upstream of Il1rn were identified as the strongest known genetic determinants of circulating IL1RN concentrations. The authors developed a
genetic score combining the alleles of those two common variants and compared it with the effects of anakinra (recombinant IL1RN) on inflammatory biomarkers in rheumatoid arthritis (RA), diabetes mellitus type 2, coronary heart disease, stroke and aortic aneurysm in a total of 453411 participants. For each IL1RN minor allele inherited, there was a significant decrease of IL6 and hsCRP that correlated with the effect of anakinra. Interestingly, individuals with increased number of inherited minor alleles (corresponding to higher IL1RN levels) showed decreased risk of RA but, surprisingly, increased CV risk (CAD, ischemic stroke and abdominal aortic aneurysm) [33]. IL1RN minor alleles were also associated with a significant increase of circulating lipoproteins like LDL-cholesterol. However, the latter only explained 33% of the increase in CV risk associated with IL1RN genotype. Thus, similarly to experimental data, translational human data remain inconclusive regarding the direct role of IL1 the pathogenesis and complications of CV diseases.

**Clinical trials:** During the last 15 years several molecules have been used to modulate IL1 pathway in autoimmune and chronic inflammatory diseases. Anakinra was the first selective inhibitor of IL1 pathway approved by the FDA to treat several autoinflammatory diseases like RA [34] and it is now undergoing clinical trials to treat other immune-mediated diseases. The effect of anakinra in CV disease was tested in a Phase II, multi-center, placebo-controlled trial, comparing the administration of a subcutaneous (s.c.) daily injection of anakinra (100 mg) for 14 consecutive days in non-ST elevation ACS patients. Anakinra significantly decreased CRP levels compared to placebo during the treatment period. However, a rebound of CRP was observed after treatment discontinuation in the anakinra group. Furthermore, major adverse cardiac events were significantly increased in the anakinra group after 1 year of follow-up [35]. Another important limitation of anakinra is its short-half life requiring frequent injections or high doses, which may be very inconvenient for the patient.

Owing to its specificity and long half-life, antibody-based neutralization of IL1β is emerging as a more attractive therapeutic strategy. Canakinumab, is a specific IL1β neutralizing monoclonal antibody that has recently been approved by the FDA for the treatment of several auto-inflammatory diseases (i.e. cryopyrin-associated periodic syndromes). It is being tested in the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS), which is currently testing the impact of IL1β inhibition as compared to placebo on recurrent CV events (MI, stroke, and CV death). Stable post-myocardial infarction (MI) CAD patients who remained at high CV risk as revealed by persistent elevations of CRP (>2 mg/L) despite contemporary secondary prevention strategies have undergone random assignment to s.c. canakinumab 50 mg, 150 mg or 300 mg or placebo every 3 months (in addition to standard pharmacological treatment). This trial is conducted in more than 40 countries worldwide in 146 centers and will recruit 17,400 patients [36]. Pilot data are available from 556 men and women who were randomly allocated to s.c. placebo or canakinumab (5, 15, 50 or 150 mg monthly) and followed up for 4 months. There were dose-dependent and significant decreases of hsCRP, IL6 and fibrinogen levels in canakinumab-treated patients compared to placebo [37]. However, there was also a modest but significant increase in circulating triglycerides levels related to the high doses of canakinumab, which might offset, at least in part, the favorable anti-inflammatory profile. The effect of canakinumab on major CV events will be reported in 2017.
Colchicine, a natural component originally extracted from plants (genus *Colchicum*) that has been used to treat gout for centuries, is now also being considered for the treatment of atherosclerotic disease. Gout is an inflammatory disease characterized by the deposit of sodium urate crystals that act as DAMPs and activate the inflammasome/IL1β pathway. Colchicine inhibits inflammasome activation in neutrophils as it forms a tubulin-colchicine complex that prevents the formation of microtubules [38]. Microtubules are necessary for the transport of NLRP3 to the mitochondria for correct assembly of the inflammasome. Since cholesterol crystals activate the inflammasome pathway in a manner very similar to urate crystals, colchicine is now considered as potentially useful in treating CAD and acute CV events. Short-term administration of colchicine significantly limits local (heart circulation) but not systemic production of IL1β, IL6 and IL18 in ACS patients, suggesting a selective anti-inflammatory effect [39,40]. The low dose colchicine (Lo-Do-Co) clinical trial was a prospective, randomized, observer-blinded endpoint design in 532 patients with stable CAD who randomly received a low dose of colchicine (0.5 mg/day) or placebo (besides standard pharmacological treatment) for 3 years. The addition of colchicine to these patients significantly reduced the risk of fatal CV event [41]. A recent meta-analysis of colchicine trials, including those in pericarditis, points towards an overall benefit on CV risk reduction [42]. However, it should be acknowledged that data interpretation or validity may be significantly limited by the lack of blinding, lack of placebo control, and a high rate of dropouts in patients assigned to colchicine.

**Methotrexate**

**Pathophysiological pathway:** Methotrexate (MTX) is an antimetabolite approved by the FDA for use in some neoplastic diseases, severe psoriasis and adult RA. MTX was originally designed as an antagonist for folic acid. At high doses (used for several cancers), it blocks dihydrofolic acid reductase impairing purines and pyrimidines synthesis and thereby DNA synthesis and replication of tumor cells. In 1951, MTX was first introduced to treat RA based on the rationale that it should inhibit proliferation of leukocytes and other cells that accumulate in the inflamed joints [43]. Low doses of MTX have an anti-inflammatory effect, based on the clinical observation that they decrease the levels of pro-inflammatory mediators, but the precise anti-inflammatory mechanism is still unresolved. Several hypotheses may tie together to explain the anti-inflammatory effect of MTX:

1. Folate antagonistic action, whereby MTX may inhibit T cell proliferation at sites of joint inflammation in RA [44]. However, administration of folic and folinic acid does not decrease its anti-inflammatory effect [45].

2. Inhibition of potentially toxic transmethylation compounds leading to a decrease of polyamines. Despite polyamines having some anti-oxidative properties, their excessive accumulation and subsequent catabolism may increase the generation of toxic NH₃ and H₂O₂ [46]. MTX inhibits the synthesis of tetrahydrofolate that is necessary for the synthesis of methionine, S-adenosylmethionine and downstream polyamines. However, drugs used to inhibit the formation of these polyamines like 3-deazaadenosine did not exert any positive effect on RA, mainly because a correct cellular content of polyamines is necessary for their antioxidative functions.

3. Increased concentrations of extracellular adenosine: MTX is metabolized in the liver to 7-hydroxy-MTX and converted into polyglutamated MTX. These
polyglutamates inhibit 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) formilase leading to intracellular AICAR accumulation. AICAR accumulation leads to enhance release of adenine nucleotides and their extracellular conversion to adenosine. Adenosine exhibits several anti-oxidant and anti-inflammatory effects. AICAR may also activate AMPK to inhibit macrophage inflammatory responses [47]. Despite all these potential mechanisms of action, it is still unclear how MTX exerts its anti-inflammatory response.

**Experimental evidence:** Evidence that MTX could be useful in the treatment of CV diseases derives from clinical trials in RA patients where MTX treatment was associated with a significant reduction of fatal CV events [48]. Paradoxically, very few experimental studies were launched to elucidate its direct role in CV disease. In one experimental study, MTX significantly decreased atherosclerotic plaque formation in rabbits fed a high cholesterol diet, and was associated with decreased macrophage migration and reduced apoptosis within the plaque [49]. In a murine model of inflammatory vasculopathy, administration of low dose MTX significantly reduced intramyocardial vasculopathy and attenuated end-organ damage. In that study, MTX up-regulated AMPK-CREB pathway in EC, activating a cytoprotective program [50].

*In vitro* experiments suggested that the atheroprotective role of MTX could also rely on enhanced reverse cholesterol transport and impairment of foam cell formation. Treatment of human blood monocyte-derived macrophages with MTX significantly increased adenosine, which activated 27-hydroxylase through A2A receptors. Increased generation of 27-hydroxycholesterol up-regulated ABCA1 gene expression, possibly through LXR activation, thereby increasing reverse cholesterol transport [51]. The effect of MTX on inhibition of foam cell formation was also attributed to A2A receptor stimulation by adenosine presumably decreasing lectin-like oxidised LDL receptor-1 (LOX1) expression [52].

**Translational studies:** Current information on MTX and CV risk derives from observational studies and clinical trials in patients with RA, psoriasis or polyarthritis treated with MTX, in whom CV events were reported. Several meta-analysis of those studies reached the same conclusion that MTX administration is associated with a significant decrease in CV events [48,53–56]. One of the largest cohort studies (n=16,752) detected a 35% decrease in CV morbidity in the group treated with MTX compared to non-MTX treated patients after a follow-up of 4 years [57]. Another study that recruited a total of 6,707 veterans with RA on database (90% males and 10% females) compared the effect of low to high-dose of MTX on the incidence of CV morbidity. The study reported a 35% significant decrease in CV morbidity on low-dose MTX, while no effect on morbidity was found in the high dose treated group [58].

**Clinical trials:** Based on those encouraging results and the relative security of MTX use in RA, it has been hypothesized that MTX could be beneficial to patients who do not present with RA but are at high risk of CV events. Additional advantages of MTX in the setting of CV disease include its safety profile at low doses and the fact that it does not affect lipoprotein metabolism in an unfavorable manner, as it is the case for some other anti-inflammatory drugs. The first trial, Cardiovascular Inflammation Reduction Trial (CIRT), has been funded by the NHLBI and is currently evaluating the effect of low-dose MTX (target dose, 15–20
mg/wk) as compared to placebo on the reduction of major vascular events. The trial will include 7,000 patients with prior MI who are already diagnosed either with diabetes type 2 or metabolic syndrome. The primary endpoint is a composite of non-fatal MI, stroke, and CV death [59]. The trial is expected to provide an interesting complementary therapeutic strategy for the secondary prevention of CV events.

**IL6 pathway**

**Pathophysiological pathway:** IL6 is a pleiotropic cytokine with a wide range of biological activities in inflammation and immune regulation. All members of the IL6 family bind to the signal transducer of cytokines related to IL6 called glycoprotein 130 (gp130) exerting pleiotropic effects (reviewed in [60]). IL6 binds the 80 kDa type I transmembrane glycoprotein termed membrane IL6 receptor (mIL6R), and gp130. This complex IL6-mIL6R-gp130 activates the classical IL6 signal transduction pathway [61]. mIL6R is only expressed on the surface of some cell types like hepatocytes, neutrophils, and some types of macrophages and T cells; thus classical activation is restricted to those cells. IL6 pathway activates JAK tyrosine kinases and promotes the recruitment and phosphorylation of STAT3 to induce downstream effector responses, for example, activation of the inflammatory acute phase response (APR) (i.e., CRP and fibrinogen production) in hepatocytes [62]. This is counterbalanced by the activation of the suppressor of cytokine signaling 3 (SOCS3), which binds to gp130 inhibiting JAK activity [63]. Intriguingly however, in the absence of SOCS3, prolonged activation of STAT3 by IL6 switches downstream responses towards the activation of an anti-inflammatory program [64]. IL6 also activates IL4 receptor expression in macrophages, thus promoting their polarization into an anti-inflammatory M2 phenotype [65]. Thus, depending on local cues, IL6 may exert both pro and anti-inflammatory effects.

IL6 pathway is even more complicated due to the ubiquitous expression of gp130 and the presence of a soluble IL6R, allowing trans-signaling even in the absence of the mIL6R [66]. There are two potential mechanisms that lead to the formation of sIL6R. The first one involves the proteolytic cleavage of the mIL6R and is dependent on metalloproteases of the ADAM family (specifically ADAM10 and ADAM17). The second one implies an alternative splicing mechanism of IL6R mRNA and has been described in humans but not in mice. Homodimers of gp130 are unable to activate the IL6 cascade just through binding to IL6. However, they do so in the presence of sIL6R. IL6 trans-signaling is therefore very important for cells that do not express mIL6R at any stage of development or activation. Several mechanisms related to atherosclerosis, such as T cell trafficking and proliferation, or activation of EC and SMC, may be independent of mIL6R but regulated through IL6 trans-signaling [67].

The glycoprotein gp130 is also present in a soluble form, mainly the result of alternative splicing [68]. Soluble gp130 can bind the IL6-sIL6R complex acting as a competitive inhibitor and impairing trans-signaling.

Classical and trans-signaling would be expected to have the same effect upon IL6 production. However, experimental results point to the activation of differential downstream responses depending on the cell type and the state of cell activation [69]. Thus, it is be very important to consider the specific contribution of classical...
and \textit{trans}-activation to the development of a CV disease in order to propose specific and accurate therapeutic strategies.

\textbf{Experimental evidence:} Experiments in mice performed to study the role of IL6 in atherosclerosis have led to controversial and unexpected results. Exogenous and sometimes supra-physiological IL6 injections were reported to enhance atherosclerosis, in part due to increased oxLDL uptake by macrophages in \textit{Apoe}-/- mice [70,71]. However, \textit{Apoe}-/-/	extit{Ili6}-/- mice presented larger and more calcified atherosclerotic plaques compared to \textit{Ili6}-/+/	extit{Apoe}-/- mice after the consumption of a normal chow diet for 1 year [72]. These results were also corroborated in C57BL6 \textit{Ili6}-/- mice fed a Paigen diet for 15 weeks, which exhibited larger fatty streak lesions than their WT littermates [73]. \textit{Ldlr}-/-/\textit{Ili6}-/- developed atherosclerotic plaques that were comparable in size to those seen in their \textit{Ldlr}-/- littermates, despite showing a significant decrease in acute phase reactants [74]. Thus, currently there is more experimental evidence that argues in favor of a protective rather than detrimental role of IL6R signaling in atherosclerosis. Studies performed with gp130 loss and gain of function models are also far from conclusive. Specific gp130 hepatic deletion in \textit{Apoe}-/- mice significantly decreased APR reactants and atherosclerotic plaque formation. However, gp130 overexpression in \textit{Apoe}-/- was associated with reduced (or no change in) atherosclerotic plaque formation despite increased production of APR reactants and macrophage infiltration [75].

On the other hand, the contribution of IL6-\textit{trans} signaling to atherosclerosis has not been studied thoroughly. Based on the only experiment that has been reported so far, IL6 \textit{trans}-signaling is considered as an important contributor to atherogenesis [76]. \textit{Ldlr}-/- mice treated with recombinant sgp130-Fc (to selectively block IL6 \textit{trans}-signaling) showed significant reduction in the development of atherosclerosis, which was attributed to a decrease of EC activation and SMC migration. Nevertheless, results from that experiment may be biased due to the fact that the control group was injected with saline and did not receive a human control IgG to match the experimental group that received sgp-130Fc of human origin. Thus, further validation experiments are needed to better elucidate the contribution of IL6 \textit{trans}-signalling to atherosclerosis.

\textbf{Translational studies:} IL6 is highly expressed in atherosclerotic plaques, but whether it exerts a pro- or anti-atherosclerotic role remains unclear, as both pro- and anti-inflammatory properties have been reported. For example, IL6 signaling pathway enhances vascular cell activation but also promotes SMC survival. It activates T cells and promotes their differentiation towards the Th17 subset, with either pro- or anti-atherogenic properties (see below). IL6 also promotes an anti-inflammatory macrophage phenotype and may enhance the synthesis of IL1RN and the production of soluble TNF receptor.

Epidemiological studies in general found a significant association between high IL6/sIL6R levels and CV risk [77–80] without providing any causal explanation. More recent Mendelian randomization studies tried to address the issue of casualty and focused on a SNP in the IL6R that was highly associated with increased circulating concentrations of IL6 and sIL6R [81,82] but reduced expression of mIL6R. Both studies found that the IL6R SNP \textit{rs2228145} (IL6R Asp158Ala) was not associated with lipid concentrations, blood pressure, adiposity, dysglycemia or smoking. Nevertheles, the 358\textit{Ala} variant was associated with a significant decrease of CRP and fibrinogen levels, and reduced
risk of CV disease. The data was interpreted as a proof that reduced IL6 signaling was responsible for the reduced risk of CVD. It is intriguing to note however that others have linked the same polymorphism to increased risk of asthma and interpreted their results as a proof-of-concept that increased (not decreased) IL6 signaling was responsible for the increased risk of asthma [83,84]. Thus, the same IL6R polymorphism is associated on one hand with increased risk of asthma, pushing investigators to propose IL6 blockade as a strategy to treat the disease, and on the other hand with reduced risk of CVD, leading investigators to support IL6 blockade as a promising strategy to reduce CVD risk. This testifies to our limited knowledge about the true impact of that polymorphism on IL6 signaling. Soluble Il6R is believed to act as an IL6 buffer system limiting IL6 signaling. However, as explained above, sIL6R binding to IL6 also activates IL6 trans-signaling pathway in cells that only express gp130. Thus, it remains plausible that individuals with the 385Ala variant may show decreased classical activation due to reduced mIL6R, which perfectly explains the decrease in acute phase proteins, but may display increased (not decreased) trans-signaling due to increased IL6 and sIL6R levels. Another polymorphism in the human gp130 homologue, IL6 signal transducer was reported to be associated with CAD. However, the association was mostly limited to the ostium of the coronary arteries in very selected patient populations [85]. Thus, further studies are needed to elucidate the role of classical and trans-signaling of IL6 in the human setting.

Clinical trials:
Several antibodies were designed to inhibit the IL6 pathway and have been used in phase II and III clinical trials to study their efficacy in RA, and other autoimmune diseases and certain cancers. Tocilizumab is a monoclonal humanized antibody of the IgG1 class that was generated by grafting the complementarity determining regions of a mouse anti-human IL6R antibody onto human IgG1. It blocks IL6-mediated signal transduction through inhibition of mIL6R and sIL6R. Its use to treat RA has been approved in more than 90 countries worldwide. Data regarding the safety of tocilizumab have been collected from RA patients and the overall safety profile is consistent across all global clinical studies. Patients with RA present increased risk of fatal CV accidents, but paradoxically they also present with lower cholesterol levels. Treatment with tocilizumab in RA patients has been associated with a significant improvement of the disease, but was associated with increased circulating levels of total cholesterol and triglycerides [86,87]. The results were corroborated in several trials. In the ADACTA (Adalimumab Acterma) phase IV clinical trial, monotherapy with tocilizumab was compared to adalimumab (anti-TNF monoclonal antibody) in MTX refractory RA patients. Tocilizumab treatment was associated with greater reduction in CRP and other anti-inflammatory composites compared to adalimumab, despite increasing circulating lipid levels [88]. Tocilizumab effect on lipid parameters is probably unrelated to direct blockade of IL6 signaling as it was not observed in individuals carrying the IL6R variant 358Ala [81,82]. It is also argued that while all lipoproteins are increased with tocilizumab, LDL/HDL, TC/HDL and ApoB/ApoA1 ratios, which predict CV risk more accurately than other lipid parameters, remain the same, suggesting little direct impact of lipoprotein changes on CV risk. Several phase IV clinical trials have tried to provide insight into this paradoxical effect on lipids studying not only quantitative but also qualitative lipoproteins changes in RA patients treated with tocilizumab. As an example, treatment with tocilizumab
on top of MTX did not significantly increase pro-atherogenic small dense LDL, but significantly increased (non-atherogenic) small and medium HDL particles, in comparison to MTX alone. Paraoxonase 1 was increased, and HDL-associated serum amyloid A and sPLA₂-IIa were decreased after tocilizumab, suggesting that IL6R blockade may promote an HDL translational change into a less inflammatory state [89]. However, circulating levels of HDL-cholesterol and sPLA₂-IIa are only markers of CV risk and have both been invalidated as causal factors in human CAD (see below for sPLA₂). In the double-blind phase of the five core studies of tocilizumab, a decreased number of MI were reported with all tocilizumab doses [90]. However, more evidence is needed regarding the impact of tocilizumab on CV events in patients with RA before starting trials to test the efficacy of tocilizumab in CV diseases outside the RA field.

**Lp-PLA₂**

**Pathophysiological pathway:** Phospholipases A₂ (PLA₂) belongs to a superfamily of enzymes that hydrolyses glycerophospholipids at the position sn-2, producing non-esterified fatty acids (p.e. arachidonic acid and lysophospholipids). PLA₂ are classified as either cytosolic or extracellular, lipoprotein associated PLA₂ (Lp-PLA₂) and secreted PLA₂ (sPLA₂) belong to the latter group of enzymes. Lp-PLA₂ is a Ca²⁺-independent 45kDA secreted protein that circulates in plasma associated with lipoproteins. In healthy individuals, it is typically associated to LDL and to a lesser extent to HDL and lipoprotein a (Lp-a) (extensively reviewed in [91]). It is widely secreted by immune cells involved in atherosclerosis such as macrophages, T lymphocytes and mast cells. It exhibits phospholipase and lipase activities. It was first discovered for its ability to hydrolyze platelet-activator factor (PAF) and so was called PAF-acetylhydrolase, but it also hydrolyzes oxPL. By cleaving an oxidized phosphatidylcholine component of the lipoprotein particle, it generates potent proinflammatory and proatherogenic mediators like oxidized non-esterified fatty acids, arachidonic acid and lysophosphatidylcholine (LysoPC). OxPL and fatty acids may promote atherosclerosis through a range of mechanisms (extensively reviewed in [91]). The effects of cyclooxygenases and lipoxygenases on arachidonic acid may generate proatherosclerotic mediators such as thromboxanes and leukotrienes. LysoPC increases endothelial activation, monocyte recruitment and differentiation into M1 pro-inflammatory macrophages.

**Experimental studies:** Several studies found an atheroprotective role of Lp-PLA₂ in Apoe⁻/⁻ mice and in a post-angioplasty restenosis model in rabbits [92,93]. Nevertheless, Lp-PLA₂ is bound to HDL in mice, while it is attached to LDL in humans. Thus, murine experimental studies were not considered to be very informative. In hypercholesterolemic minipigs however, a correlation was found between oxLDL, lysoPC and Lp-PLA₂ levels resulting in accelerated atherosclerosis [94]. On the other hand, diabetic/ hypercholesterolemic swines treated with darapladib (a selective pharmacological inhibitor of Lp-PLA₂) presented a significant decrease of lysoPC in lesions, associated with significant, although modest, reduction of atherosclerotic plaque size and necrotic core area [95].

**Translational studies:**

Lp-PLA₂ was demonstrated to be highly up-regulated in macrophages located in the lipid core and fibrous cap of vulnerable and ruptured human coronary arteries, but not within stable lesions [96]. The reason for this may be due to the fact that pro-inflammatory macrophages M1 (more abundant in the necrotic core of
unstable plaques) secrete much higher amounts of this enzyme than the anti-inflammatory M2. Indeed, patients with a previous episode of CV event express higher Lp-PLA2 and lysoPC than patients with no CV history, suggesting a potential role of Lp-PLA2 in plaque composition and vulnerability.

Several epidemiological studies (reviewed in [91]) tried to elucidate the potential prognostic value of Lp-PLA2 in CAD but reached opposite conclusions. A meta-analysis evaluating data from 36 prospective studies with a total sample size of 126,634 patients concluded to a modest association between Lp-PLA2 concentration, but not activity, with CAD [97]. However, another meta-analysis analyzing data from 79,036 individuals in 32 prospective studies found a significant correlation between Lp-PLA2 mass or activity and CAD [98]. Several polymorphisms have been related to different levels of Lp-PLA2 activity. However, inconsistent results were reached regarding their association with CAD. A missense polymorphism Val279Phe in PLA2G7 gene is present in approximately 30% of the Japanese population, and heterozygotes or homozygotes carriers of this polymorphism display reduced or no catalytic activity respectively; those individuals are not protected from CAD. A meta-analysis compiling information from 14 association studies focusing on 3 polymorphisms A379V, V279F and R92H, concluded to an association between R92H allele and increased CV risk, but that variant was not associated with significant changes of Lp-PLA2 activity. The other 279F and 379V variants were associated with decreased Lp-PLA2 activity but were not associated with CHD risk [99]. Finally, in a recent study, carriers of loss-of-function variant in PLA2G7 (rs140020965; Q287X) had almost 3-fold lower levels of Lp-PLA2 activity but no difference in risk of incident CAD compared with non-carriers [100].

Clinical trials

Darapladib was developed as a potent and reversible oral inhibitor of Lp-PLA2. Based on some epidemiologic studies supporting an association between Lp-PLA2 and CV risk, several clinical trials were launched to assess the effect of darapladib on CV events in patients with stable or unstable CAD. After two encouraging phase II clinical trials [101,102], two phase III clinical trials were launched. In the STABILITY (Stabilization of Atherosclerosis Plaque by Darapladib Initiation of Therapy) trial, 15,828 patients with stable CAD were randomly assigned to darapladib 160 mg/day or placebo (on top of optimal treatment) for a total of 3.7 years. Unfortunately, darapladib did not reduce the incidence of the primary endpoint, a composite of CV death, MI or stroke [103]. Some have argued that the negative result could be explained by the fact that those patients were already on statins, drugs with a very important impact on cholesterol levels (both groups presented LDL levels below 70 mg/dL) and Lp-PLA2 (it has been previously reported that statins reduce Lp-PLA2 levels by 35%). The second phase III clinical trial, SOLID-TIMI 52 (the Stabilization of Plaques Using Darapladib-Thrombolysis in MI 52 Trial) evaluated the effect of darapladib (160 mg/day) vs. placebo in 13,026 patients with ACS for an average period of 2.5 years. Again darapladib treatment did not improve the primary endpoint of major CV events [104]. Overall, the use of darapladib is not recommended for the treatment or prevention of CV events.

sPLA2

Pathophysiological pathway: sPLA2 are a group of enzymes with low molecular weight (from 14 to 19 kDa) and a Ca^{2+}-dependent phospholipase activity. Various
sPLA₂ may exhibit independent non-redundant roles. They are localized in different chromosomes, though 6 of them reside in the same gene cluster. Among them, the sPLA2-II/V cluster has been described in humans to be a candidate susceptibility locus. Both, sPLA2-II and V are increased by proinflammatory stimuli and are downregulated by anti-inflammatory cytokines. sPLA2-II accumulates in inflammatory fluids (p.e. synovial fluid in patients with RA) and is constitutively expressed in organs dealing with inflammatory responses like spleen, thymus, bone marrow, intestines, ovary and lung [105]. sPLA2-V is constitutively expressed in different tissues but mainly in the heart.

sPLA2-II, III, V and X are able to hydrolyse phosphatidylcholine in LDL leading to the formation of unsaturated fatty acids and lysoPC. They also give rise to the formation of smaller and denser LDL and enhance foam cell formation, potentially exhibiting an important role in the initiation of atherosclerosis. Because sPLA2-III, V and X are not detected in high concentrations in serum, they are believed to exert their actions on LDL accumulated in the intima. sPLA2-IIA is the predominant isoform in serum and the arterial wall, and despite having a modest LDL hydrolyzing activity, its high levels may somehow compensate for its low activity.

sPLA2 also exhibit non-enzymatic roles, through binding to M-type receptors on neutrophils, monocytes and macrophages, inducing pro-inflammatory cytokines and chemokine production.

**Experimental evidence:** C57Bl6 mice have a natural null mutation in the sPLA2-IIA gene (Pla2g2a), thus several mouse lines overexpressing different human sPLA2 have been developed. Transgenic Pla2g2a C57Bl6 mice presented bigger atherosclerotic lesions than their WT littermates after the consumption of a high fat diet [106]. The same results were obtained in Ldlr⁻/⁻ transplanted with BM from Pla2g2a Tg mice and macrophage-specific Pla2g2a Tg mice, thus confirming an atherogenic role of sPLA2-IIA in mice [107].

Transplantation of Ldlr⁻/⁻ with BM from transgenic Pla2g5 gene promoted increased atherosclerotic plaques [108]; whereas mice transplanted with Pla2g5⁻/⁻ BM had reduced atherosclerotic lesion size and collagen deposition in comparison to their WT littermates [108]. Nevertheless, Apoe⁻/⁻ mice with deficiency in Pla2g5 did not show decreased atherosclerotic plaques despite lower collagen deposition. These controversial results were attributed to differential enrichment of Apoe⁻/⁻ (compared to Ldlr⁻/⁻)-derived LDL in sphingomyelin, which alters sPLA2-V hydrolytic activity.

sPLA2-X shows the most potent hydrolyzing activity toward PC, suggesting a proatherogenic role. However, Ldlr⁻/⁻ transplanted with BM from mouse group X-deficient mice (Pla2g10⁻/⁻) surprisingly had bigger atherosclerotic plaques. Also, overexpression of human PLA2G10 in murine bone marrow cells led to significant reduction of Th1 response and atherosclerotic plaque development, challenging the pro-atherogenic paradigm of sPLA2 activity, and suggesting that inhibition of total sPLA2 activity may lead to detrimental CV effects [109].

Varespladib (from Anthera Pharmaceuticals) is a drug that specifically inhibits – sPLA2-IIA, V and X but does not act on sPLA2-III. Its protective role on atherosclerosis has been tested in 2 different studies using Apoe⁻/⁻ mice. Varespladib used alone significantly decreased atherosclerotic plaque formation and aneurysm development when compared to non-treated animals [110]. In the second study, varespladib was used in combination with a statin (pravastatin) at low doses; this combined effect decreased atherosclerosis to a bigger extent than
each drug on its own, supporting a potential synergistic effect between these two drugs [111].

**Translational studies:** Several epidemiological studies tried to address the potential prognostic value of sPLA₂ in atherosclerosis. Elevated sPLA₂-IIA levels have been associated with increased CV risk in several cohorts of patients with stable CAD [112–114]. The largest study that confirmed the prognosis value of sPLA₂ in stable CAD patients was the PEACE study where elevated levels of sPLA₂ were significantly associated with the risk of CV disease, MI and stroke, even after multivariate adjustment including Lp-PLA₂ and CRP [115]. Disappointingly however, Mendelian randomization studies did not support a causal role for sPLA₂ in CHD [116,117].

**Clinical trials:** Several clinical trials have been launched to study the security and efficacy of varespladib in CAD. PLASMA I (phospholipase levels and serological markers of atherosclerosis) was a phase II, randomized, double-blind and placebo-controlled, parallel-arm, dose-response clinical trial to evaluate the effect of 4 different doses of varespladib in 396 patients with stable CAD [118]. The aim was to study the effect of an 8-week treatment on sPLA₂-IIA levels, oxLDL, hsCRP, LDL particle size, plasmatic arachidonic acid and leukotriene B4 levels. The authors reported a dose-dependent decrease in sPLA₂-II (reaching up to 90% in treated vs. 5% in placebo) in patients treated with varespladib. Treatment also led to an 8% significant decrease of LDL levels in comparison to placebo. No significant changes were found in any other CV biomarker. PLASMA II was also a phase II, randomized, placebo-controlled study that was launched to study the effect of a daily single dose of varespladib (two different doses, 250 and 500 mg) in 197 patients with stable CAD, and reached the same conclusion as PLASMA I [119].

Another phase II clinical trial called FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression) was designed to examine the impact of 500mg of varespladib or placebo in association with atorvastatin 80 mg daily administered to patients within 96 hours of an ACS event and for 6 months. Varespladib treatment successfully reduced cholesterol, CRP and sPLA₂-IIA levels [120]. These results led to a phase III clinical trial VISTA-16 that included more than 5,000 patients worldwide. Despite achieving lower cholesterol and CRP levels, patients treated with varespladib were not protected against the recurrence of CV events. The trial was stopped before completion due to increased incidence of MI in the varespladib group. Thus, varespladib may be harmful and is not a useful strategy to reduce adverse CV outcomes after ACS [121]. The results could have been predicted based on some experimental [109] and Mendelian randomization studies [116,117].

**Therapies targeting the adaptive CD4⁺ T cell immune response**

The adaptive immune response is a specialized response. Innate immune cells, mainly macrophages and DC, act as antigen presenting cells (APC) and initiate the adaptive immune response. They drive the maturation and polarization of naïve CD4⁺ T cells through exposure of antigenic peptides on major histocompatibility complex class II molecule (MHCII), along with the engagement of co-stimulatory pathways. The antigenic epitopes that drive specific adaptive T cell immune responses in atherosclerosis are still to be characterized. However, an increasing body of evidence suggests a potential role for oxidized or native ApoB100-derived
epitopes, but antigens derived from heat shock protein 60/65 or other proteins may also play a role [122,123]. Activated T cells will differentiate into specific Th subtypes that secrete specific sets of cytokines and provide help to B cells favoring isotype switching, antigen-specific antibody production and induction of antibody-producing plasma cells. The role of B cells in atherosclerosis has previously been published in this journal [124]. Therefore, we will focus here on the role of T cells. Primed naive T cells can differentiate into at least 4 major T cell subtypes: Th1, Th2, Th17 and T regulatory (Tregs) cells. Polarization is induced by DC presenting antigens through MHCII to the TCR and interaction with co-stimulatory molecules like CD80, CD86, CD40 and OX40, binding to CD28, CD40L and OX40L on T cells. Additional soluble or membrane bound factors contribute to T cell polarization, e.g., IL12 and IL18 favor Th1 differentiation, CCL2, IL13 and IL6 may drive Th2, and TGFβ, IL6 and IL1β promote Th17. Treg polarization requires MHCII-TCR binding along with low level co-stimulation through CD80/CD86 with CD28, CD80/CD86-CTLA4 and/or ICOS-ICOSL. All types of Th and Treg cells have been found in human atherosclerotic plaques, Th1 being the most prevalent. In general Th1 and its signature cytokine IFNγ play an atherogenic role and their detrimental role in atherosclerosis has been extensively reviewed previously. Unfortunately, therapeutic tools that specifically target the Th1 response are not currently available. We will therefore focus on the other T cell subtypes.

**Th17:**

**Pathophysiological pathway:** Specific polarizing cytokines are required for Th17 differentiation. In mice, TGFβ represses Th1 and Th2 transcription factors, allowing IL6 to induce Th17 differentiation. IL6 activates STAT3 to up-regulate retinoic acid orphan receptors (ROR) α and γ, leading to the induction of the Th17 program. Also, in the absence of TGFβ, IL6 and IL23 in conjunction with IL1β may cooperate to induce IL17 secretion and induce Th17 polarization (extensively reviewed in [125]). Upon activation, Th17 cells produce signature cytokines IL17, IL21 and IL22. However, Th17 do not represent a homogeneous subset, and can be reprogrammed into other T cell subsets depending on the cytokine environment. In fact, IL17 can be co-expressed with other cytokines like IFNγ, IL10 and IL4. Th17 may exhibit plasticity between Th1 cells and Tregs: a Th1/Th17 subset that co-expresses Tbet and RORγt has been found in some autoimmune settings, and a subset of RORγt+ T cells that co-expresses Foxp3+ has also been identified. These recent findings involving Th17 plasticity may account for their controversial role in atherosclerosis.

The IL17 family includes 6 members, IL17A (known as IL17) to IL17F (known as IL25), that all bind to IL17 receptor (IL17R), which consists of 5 subunits (IL17RA-IL17F). IL17RA is ubiquitously expressed throughout the body, resulting in a wide range of pleiotropic actions of IL17. IL17 enhances several pro-inflammatory signaling pathways including NF-κB and MAPK, which activate downstream target genes with important implications in atherosclerosis, mainly CXCL1 and 2 (involved in neutrophils and monocyte chemoattraction), IL6, IL1, MMPs and granulocyte MCSF.

**Experimental evidence:** The role of Th17 has widely been studied in mouse models of atherosclerosis, and has been shown to exert both pro and anti-atherogenic effects (extensively reviewed in [125]). This is true for models using
I\textsubscript{l}17A\textsuperscript{−/−} mice, IL17A blocking antibodies, IL17A recombinant protein, or any other methodology used to down- or up-regulate IL17A signaling [126–133]. A recent experiment that had not been discussed in the previous review on the role of IL17 signaling in atherosclerosis[125], reported significant reduction of atherosclerotic plaque formation and increased stabilization after administration of a mouse anti-mouse IL17A antibody to 32 weeks-old Apoe\textsuperscript{−/−} mice fed a control chow diet [134]. However, we believe that the validity of this new study is compromised by the fact that the reported lipid profile (equivalent levels of total cholesterol and LDL-C at around 200 mg/dl) did not correspond to an Apoe\textsuperscript{−/−} mouse. Thus, our current interpretation of the bulk of experimental studies on the role of IL17 signaling in atherosclerosis is the following: Atherosclerotic mouse models are mostly driven by a Th1 response; if both Th1 and Th17 are increased, the outcome will be increased atherosclerosis; however, if IL17 induction leads to limitation of Th1 responses, the outcome will most likely be a protection against exacerbated atherosclerosis.

**Translational studies:**
Robust evidence shows that IL17 mediates adverse effects in RA, multiple sclerosis, systemic lupus erythematosus, and psoriasis [135] but less is known about its potential role in atherosclerosis. Increased numbers of T cells expressing IL17 were found in atherosclerotic plaques [134]. Recombinant IL17 increased monocyte cell adhesion to EC in vitro, promoted macrophage polarization into a pro-inflammatory phenotype, and increased MMP9 secretion by ex vivo plaque cultures. On the other hand, work from our lab suggested an atheroprotective role for IL17. IL17 was expressed not only by T cells, but also in normal SMC from healthy human arteries. Intriguingly, IL17 expression was significantly decreased in medial SMC underlying atherosclerotic plaques, although its expression was still detected in plaque T cells. Recombinant IL17 reduced EC activation (VCAM1 expression) in culture, and high IL17 levels in human plaques were associated with a decrease in macrophage content and an increase of SMC and generally, with a more stable plaque [131]. Other investigators have subsequently corroborated the latter findings [136].

A very few epidemiological studies addressed the association between Th17 levels in blood and CV risk. One study found a significant increase of blood Th17 cells in subjects with ACS (n=43) in comparison to patients with stable CAD or healthy controls (n=20) [137]. In another study, increased blood levels of Th1-Th17 cells were found in patients with ACS [138]. The same authors reported that Th1-Th17 cultured cells from atherosclerotic coronary arteries produced a unique combination of IL17A and IFN\textgamma after polyclonal stimulation compared with T cells from healthy vessels, inducing pro-inflammatory responses in vascular SMC [139]. However, we have shown that circulating IL17A substantially reduces human mononuclear cell adhesion to TNF \alpha-activated human umbilical vein EC, which was associated with a significant reduction of sVCAM-1 expression, despite an increase of IL6 [140]. Moreover, in a large prospective and multicentric study enrolling 981 patients after an acute MI, low levels of circulating IL17 were associated with increased (not decreased) risk of all-cause death and recurrent MI at 2 years. IL17 was also negatively correlated with sVCAM1 levels, suggesting an important role of IL17 in EC activation. Thus, further translational studies must be performed before any definitive conclusion can be reached about the potential effect of Th17 T cell subtypes in atherosclerosis.
Clinical trials:
Several neutralizing agents that inhibit IL17 signaling pathway have been developed due to their potential benefit in the treatment of autoimmune diseases. The first developed neutralizing antibody was ustekinumab, which targets the p40 subunit of the cytokines IL12 and IL23, and was approved in 2009 by the FDA to treat psoriasis. The biggest phase III Clinical Trial that demonstrated the efficacy of ustekinumab in psoriasis has already been reviewed in detail in this Journal [141]. Subsequently, at least two other IL17 neutralizing antibodies (secukinumab and ixekizumab) and one receptor blocking antibody (brodalumab) were developed and shown to be successful in Phase II Clinical Trials targeting autoimmune diseases like psoriasis. In fact, last year based on the results obtained in the CLEAR Phase III trial comparing ustekinumab and secukinumab, the latter was announced to be the first line-systemic treatment for moderate to severe plaque psoriasis. It is very intriguing however to note that in the placebo-controlled trials conducted to date, major CV events occurred only in the active arm, not in the placebo-treated group. As an example, in a recent study that addressed the effect of intravenous secukinumab (at a dose of 10 mg per kilogram) at weeks 0, 2, and 4, followed by s.c. secukinumab at a dose of either 150 mg or 75 mg every 4 weeks, or placebo for a maximum of 24 weeks, 4 strokes and 2 MI were reported in the secukinumab group [142], and none in the placebo group [143]. During the placebo-controlled phases of the anti-p40 studies, 10 of 3179 patients receiving anti-p40 therapies experienced major adverse cardiovascular events compared with zero events in 1474 patients receiving placebo. By comparison, in the anti-TNF trials, only 1 of 3858 patients receiving anti-TNF therapy experienced a MACE compared with 1 of 1812 patients receiving placebo [143]. Thus, further experiments are needed to evaluate the cardiovascular safety of anti-p40 or IL17A/IL17R blockade in the long term. In the meanwhile, we recommend that patients treated with inhibitors of IL17A pathway are regularly checked and monitored to avoid unexpected CV events.

Tregs: Pathophysiological pathway: Tregs are negative regulators of immune effector cells and are required to maintain immune homeostasis. They are essential in mediating peripheral tolerance, preventing autoimmune diseases, and suppressing inflammatory responses. There are two major classes of CD4+CD25hi Tregs, naturally occurring Tregs (nTregs) and adaptive/induced Treg cells (iTreg) (reviewed in [144]). They depend on IL2 for development and survival. nTreg comprise a 5-10% of the total CD4+ T cells in mice and humans, they mature within the thymus and they express Foxp3. Several important functions related to autoimmunity and atherosclerosis have been associated with Tregs. Fully mature nTreg cells exit the thymus, and migrate to secondary lymphoid organs (i.e. lymph nodes, spleen) [145]. Tregs also migrate to atherosclerotic arteries [146] and accumulate in tertiary lymphoid organs located in the adventitia of highly inflamed atherosclerotic vessels [147]. Tregs suppress autoimmune T cell proliferation and polarization, and inhibit polyclonal T cell activation, as well as the function of B cells, macrophages and DC. The mechanisms behind this immune suppressive role are multiple and may involve cell-to-cell contact, membrane-bound TGFβ, IL10, CTLA4 or T effector cell deprivation of IL2.
On the other hand, iTreg cells mature in the periphery from a CD4+CD25− T cell population. Upon stimulation within a favorable microenvironment (in the presence of TGFβ, IL10 or IL4, but in the absence of IFNγ, IL1, IL6 or IL12) they may become CD4+CD25+ T cells with regulatory properties and a more or less stable Foxp3 expression. In the atherosclerosis setting they suppress T cell proliferation and activation, inhibit foam cell formation and redirect macrophage differentiation into the anti-inflammatory M2 phenotype.

**Experimental evidence:** Apoe−/− mice have less Tregs in the spleen and demonstrate impaired immune suppressive properties compared to age-matched WT mice. In Ldlr−/− mice, splenic Treg numbers increase after 4, 8 and 20 weeks on high fat diet. However, the numbers of circulating and lesional Treg peak at 4 weeks and decrease significantly at 8 and 20 weeks, concomitant with increased numbers of CD4+ effector T cells and increased lesion size over that period [146]. There is extensive evidence in mice implicating an anti-atherosclerotic role for Treg cells. Significant aggravation of atherosclerosis is observed in different mouse models with depleted Tregs [144,148,149]. These include Treg deficiency due to deletion of CD80/CD86, CD28, ICOS, Foxp3-expressing T cells or Treg deficiency induced by the absence/depletion of tolerogenic DC or by injection of anti-CD25 blocking antibody. Also, depletion of Treg signature cytokines IL10 and TGFβ leads to exacerbated atherosclerosis, further supporting an atheroprotective role for Tregs.

On the other hand, adoptive transfer of CD4+CD25+ or Tr1 cells, as well as expansion of Tregs after blockade of CCL17, significantly reduced atherosclerotic lesion development in Apoe−/− [150]. Strategies for vaccination or tolerization to enhance (antigen-specific) Tregs in atherosclerosis have been developed in mice, with mixed results [151–157]. This is mostly due to our limited knowledge about the causal antigenic epitopes in atherosclerosis [158] and the subtype of DC to be targeted in order to selectively induce a Treg response [159–164]. Administration of IL2/anti-IL2 mAb complexes, which leads to sustained increase of IL2 levels and a 10-fold increase of Tregs levels in blood, resulted in a significant reduction of atherosclerotic plaque formation and progression in Ldlr−/− mice [165]. Another experiment was designed to deliver IL2 directly into the atherosclerotic plaque. IL2 was coupled to L19, an antibody that recognizes the extradomain B of the extracellular matrix glycoprotein fibronectin (ED-B), which is differentially expressed in atherosclerotic plaques. Local IL2 administration significantly decreased the progression of pre-established atherosclerotic plaques due to the activation and proliferation of intra-plaque Treg cells in Apoe−/− mice [166].

**Translational studies:** Treg are detected in much lower amounts in atherosclerotic plaques (1-5% of all T cells) than in any other inflamed tissue (25% of all T cells in eczema and psoriasis). This suggests that local T cell imbalance in the atherosclerotic plaque may play an important role in disease progression. The mechanisms behind Treg reduction in atherosclerotic tissues are poorly understood (reviewed in [144]). A small study performed in 32 patients with ACS found reduced blood levels and less activated Tregs in comparison to healthy subjects [167]. A series of small size epidemiological studies corroborated those results [137,168,169]. In a random sample from the prospective Malmö Diet and Cancer Study (n=700 participants between 68-73 years old), the number of circulating Tregs was inversely correlated with the development of MI and
coronary events at follow-up [170]. Treg levels have also been inversely associated with plaque instability [171].

**Clinical trials:** Adoptive Treg transfer limits the progression of CV diseases in mice, and has therefore been considered as a potential therapeutic strategy in humans though its development is being slow (extensively reviewed in [172]). Ex vivo expanded human Treg cells were effective in the prevention and treatment of graft-versus-host disease or type 1 diabetes mellitus [173,174]. But no data are available at present on the effects and safety of transferred Treg cells in patients with CV disease. Another strategy that could be applied to atherosclerosis would involve the isolation of autologous DCs, their subsequent loading with appropriate antigen(s) ex vivo (e.g., immunogenic epitopes of modified LDL), and their re-injection to the patient. However, an important challenge is to select the right antigens and to target the right DC subset (reviewed in [175]).

As explained above, IL2 is a major cytokine required for Treg generation and maintenance. Recombinant IL2 (aldesleukin) is currently available and approved for the treatment of renal cell carcinoma and metastatic melanoma. In those settings, IL2 treatment is not aimed at activation of Tregs but IL2 is administered at very high doses to activate anti-tumor T effector cell activity. Such high dose IL2 may be associated with severe CV adverse effects (e.g., vascular leak syndrome characterized by tachycardia, increased vascular permeability and hypotension) due increased T cell activation and the occurrence of a "cytokine storm". We propose to re-purpose aldesleukin for the treatment of CV diseases. Indeed, the effect of IL2 on Tregs is mediated by high-affinity IL2 receptors on Tregs. Beyond differences in receptor expression, Tregs also display exquisite sensitivity to IL2 signaling compared to T effector cells. This makes (ultra)-low dose IL2 (which will selectively activate Tregs) an interesting and potentially useful tool to readjust the homeostatic imbalance between Tregs and T effectors in cardiovascular diseases. In Phase II clinical trials, low-dose IL2 has been demonstrated to be safe and efficient in the treatment of several auto-immune mediated diseases, including hepatitis C virus-induced vasculitis or graft-versus-host disease, increasing Treg levels by at least 2 fold, without any detectable activation of effector T cells [176,177]. We are currently testing a similar approach to promote Tregs in coronary patients with the aim to reduce vascular inflammation and limit cardiovascular events.

**Th2:**

**Pathophysiological pathway:** IL4 is the key cytokine that drives Th2 differentiation. DC secreting IL6 or activated by TSLP to express OX40L promote CD4 naïve T cells polarization and differentiation into Th2. This leads to STAT6 up-regulation and induction of GATA3, which activates the expression of signature cytokines IL4 and IL5, leading to inhibition of IFNγ production (reviewed in [178]). Like other Th subsets, Th2 also exhibit plasticity. For example, TGFβ induces Th2 secretion of IL9 suggesting their conversion into Th9 cells. Due to their inhibition of Th1 polarization, an anticipated anti-atherosclerotic role was first hypothesized for Th2. However, recent data indicate that their role in atherosclerosis may depend on their cytokine profile.

**Experimental evidence:** The first observation that suggested an atheroprotective role for Th2 cells came from an experiment performed in Th2-biased BALB/c mice, which were found to be resistant to atherosclerosis in comparison to
Th1-biased and athero-susceptible C57Bl/6 mice [179]. Moreover BALB/c Stat6−/− mice showed increased atherosclerotic plaque formation when compared to their WT littermates [180].

Nevertheless, studies targeting IL4 led to controversial results. A first publication showed decreased atherosclerotic plaque formation in Ldlr−/− transplanted with BM from IL4−/− mice compared to WT [181]. But two subsequent experiments did not corroborate the results using either Apoe−/−/Il4−/− or Ldlr−/−/Il4−/− dKO mice [182,183]. More recent data suggest that selective targeting of type I IL4 receptor (IL4Rα and common γ chain) may attenuate atherosclerosis in comparison with the targeting of the type 2 receptor (IL4Rα and IL13Rα1) [184]. Currently, two Th2-related cytokines have been shown to exert anti-atherosclerotic functions. IL5 induces athero-protective antibody secretion in natural B1 cells. Transplantation of IL5−/− BM in Ldlr−/− enhanced atherosclerotic plaque formation, accompanied by a decrease in natural IgM production from B1 cells. The same authors also demonstrated that immunization of Apoe−/− mice with MDA-modified LDL reduced atherosclerosis through up-regulation of IL5 secretion and a resultant increase in natural IgM antibodies against oxidized epitopes [185]. IL33-dependent atheroprotection has also been attributed to Th2-mediated IL5 production and stimulation of B1-dependent natural IgM production [186].

IL13 is another Th2 secreted anti-atherogenic cytokine. Administration of IL13 to Ldlr−/− led to a significant decrease in atherosclerotic plaque formation and increased stability, in part through reduction of endothelial inflammation and an induction of a favorable alternative macrophage phenotype [187]. It is important to highlight though, that IL5 and IL13 are not specific to Th2 cells, and are also secreted by innate lymphoid cells 2 (ILC2), which may play significant roles in atherosclerosis.

Translational studies: Immunologically, a skewed Th1/Th2 balance due to enhancement of Th1 cells and suppression of Th2 has been associated with the pathogenesis of human atherosclerosis [123]. The protective role assigned to Th2 was initially related to the secretion of IL10, an anti-inflammatory cytokine with major protective role in atherosclerosis [188,189].

IL4, however, has not been associated with protection from atherosclerosis in humans [190]. Recent epidemiological studies found higher levels of IL4 in plasma of subjects with CAD in comparison to healthy controls [191,192]. Interestingly, an association between CAD and variants near the IL5 gene locus was identified, suggesting a potential role of a Th2-related cytokine in the progression and development of CAD [193]. In this case, a putative atheroprotective effect has been initially suggested for IL5 due to the negative correlation between its plasma levels and carotid intima thickness [194]. A larger European prospective study concluded to a weak association between IL5 levels and CV risk in women, and no association in men [195]. Moreover, recent Mendelian randomization approaches could not support a role for IL5 levels in intima-media thickness [196], and suggested alternative mechanisms to explain the relationship between SNPs in IL5 gene locus and CV risk. Nevertheless, autoantibodies against IL5 were significantly associated with peripheral artery disease in a high-throughput screening of pooled serum [197].

Clinical trials: Neutralizing antibodies against IL5 have been developed to treat severe asthma (reviewed in [198]). Given the potential atheroprotective role of IL5, we believe that we should be cautious about possible detrimental
cardiovascular effects that such anti-IL5 therapies may induce in patients with severe asthma, particular in patients at high baseline CV risk. Finally, it is interesting to note that low-dose IL2 therapy, which expands Tregs, has also been shown to promote IL5 production by ILC2 [199]. Those data favorably argue for the use of such a strategy (increasing Tregs and ILC2-derived IL5) to treat CV diseases.

**Conclusion**

It is might be disappointing to see that despite the large body of observational and mechanistic evidence that implicates immune responses in the development and complications of cardiovascular diseases, this knowledge has not been translated yet into benefit for the patient. There are several potential explanations and as discussed in the review, the failure of some trials could have been predicted on the basis of genetic Mendelian randomization studies. Another point to consider is that the various components of the immune system often play complex roles at different stages of disease development and progression and in different disease contexts, which may lead to different impact on disease outcomes. This is notwithstanding that the same cytokine or signaling pathway may differentially alter the disease process through induction of pro- or anti-inflammatory programs in different cell subtypes. Thus, the overall impact of cytokine signaling blockade on disease outcome is expected to be modest in the general population of patients with cardiovascular diseases. However, we believe that the therapeutic effect may be improved if we are able to stratify patients and assign selective therapies to appropriate patient populations, moving towards more personalized medicine.

**Expert commentary:** There is extensive evidence relating the activation of the immune system to the development and complications of atherosclerosis, and recent data in humans support a causal role for some immune-mediated pathways in disease development. Yet, we still do not know whether manipulation of the immune system will have direct impact on disease outcome. Here, we have reviewed and discussed the most relevant innate and adaptive immune pathways currently considered for targeting in this setting, at the exception of B cell-dependent responses, which have recently been reviewed in detail in the Journal [124]. We highlighted the extraordinary opportunity now offered to directly test the inflammatory hypothesis of atherosclerosis in the clinic using currently available therapeutics. However there are a few important points to keep in mind:

1. The role of a given immune-mediated pathway in atherosclerosis is often interpreted in a simplistic dichotomic way, and important subtleties are frequently dismissed. For example, IL1α and IL1β signaling pathways are pro-atherogenic. However, little importance is attached to the potential undesirable effect of IL1 blockade on lipid metabolism or plaque remodeling. IL6 pathway is almost invariably considered as pro-atherogenic despite the fact that deficiency of Il6 may be associated with acceleration of atherosclerosis. A similar comment pertains to the IL17A pathway, both in mice and in humans. Thus, a more balanced interpretation of the experimental and translational data is needed, which may help address and identify in more details the appropriate settings where an immune pathway can be targeted with minimal risk.

2. Most experimental studies focus on the development of atherosclerosis. Intriguingly, it appears that a modulation of the inflammatory response is also
critical to the regression of atherosclerotic lesions (reviewed in [200]). Thus, increased attention should be directed to the understanding of the mechanisms of progression versus regression of established atherosclerotic plaques, with the aim to identify selective modulators of atherosclerosis regression.

3. Negative results of some large phase III clinical trials could have been predicted by the results of some experimental or human genetic studies. This is for example the case for sPLA2 and Lp-PLA2 inhibitors where Mendelian randomization studies in humans were unable to detect any evidence of causal relationship between sPLA2 or Lp-PLA2 enzymes and cardiovascular diseases. Use of such genetic studies should be considered whenever possible before embarking on large phase III clinical trials.

4. However, GWAS data addressing the causal relationship between immune-mediated pathways and cardiovascular diseases should be interpreted with more caution. For example, the presence of an IL6R SNP, which is associated with higher circulating levels of sIL6R and IL6 but lower expression of mIL6R, has been interpreted as leading to increased IL6 signaling in a GWAS study that reported on the association between genetic variants and the risk for asthma [83,84], but was considered as responsible for reduced IL6 signaling in other GWAS studies that reported on the association between IL6R genotype and coronary heart disease [81,82] or abdominal aortic aneurysm [83]. This testifies to our ignorance of the true impact of that SNP on IL6 signaling, and to the urgent need for more studies to better understand the determinants and roles of classic versus trans IL6 signaling in disease development and complications.

Five Year View:
The next five years will certainly profoundly shape our understanding of the role of immune pathways in cardiovascular diseases, particularly in the clinical setting. Results of several ongoing clinical trials will be published, namely CANTOS and CIRT, and additional information will be available regarding the impact of IL6R blockade on cardiovascular risk. Several phase II and phase III trials will be initiated to further test the implication of selective immune pathways in CVD. For example, our lab will be testing low-dose IL2 therapy to limit vascular inflammation and coronary events in patients with acute coronary syndromes, and B cell depletion using CD20 mAb to reduce infarct size and improve left ventricular ejection fraction in patients with acute myocardial infarction. The discovery of new pathways involved in CVD will continue, and we expect interesting data to be available during the next 5 years on the mechanisms relating some genetic risk variants to CVD. Finally, identification of pro-atherogenic epitopes and a better understanding of antigen presentation and the role of selective dendritic cell subsets in modulating pro- and anti-atherogenic immunity will pave the way for specific manipulation of the immune system, through vaccination or tolerization, with the aim to achieve a cost-effective and sustained reduction in disease burden.

Key Issues:

- Atherosclerosis is a chronic inflammatory disease where innate and adaptive immune responses play major roles at all stages of the disease.
- Several phase III clinical trials are currently testing the immuno-inflammatory hypothesis of atherosclerosis, the most promising ones being
CANTOS (anti-IL1β) and CIRT (Methotrexate). However, failure of those trials should not detract from testing the validity of other immune-mediated pathways to reduce CVD.

- IL6R pathway is causally related to coronary artery disease and abdominal aortic aneurysm. However, more experiments are needed to clarify the specific contributions of each of the classical and trans-signaling pathways of IL6 to disease development and complications.

- Studies are needed to evaluate the long-term cardiovascular safety of anti-p40 and IL17A/IL17R blockade in patients with immune-mediated diseases. Meanwhile, we believe that those therapies should be avoided in patients at high cardiovascular risk. A similar cautious note applies to patients treated with anti-IL5 blocking antibodies.

- Promoting Treg cells, either through administration of low-dose IL2 or antigen-specific activation, may hold promise in the treatment of patients with cardiovascular diseases.

**Figure 1: Currently available clinically approved drugs that interfere with the T cell response.** Specific polarizing cytokines are required for naïve CD4+ T cells differentiation into various helper (Th1, Th2, Th17) and regulatory T cell (Treg) subsets. After stimulation Th cells secrete signature cytokines with different potential roles in atherosclerosis (protective or atherogenic). Several drugs have been developed to interfere with T helper and regulatory functions in clinical settings of immune-mediated diseases other than atherosclerosis. Some of these drugs are presented in the box in the bottom right corner of the Figure, and color-coded with their target molecule. The diagram shows that those available drugs may significantly impact atherosclerosis and cardiovascular risk either in a positive or a negative manner.

**References**


29. Tarlow JK, Blakemore AI, Lennard A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp


37. Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen a phase IIb randomized, placebo-controlled trial. *Circulation.* 126(23), 2739–2748 (2012). *CANTOS is the largest clinical trial currently ongoing testing the anti-inflammatory theory of atherosclerosis, and more particularly the efficacy of IL1β blockade on clinical cardiovascular outcome in patients with coronary artery disease. A phase IIb showed that canakinumab significantly reduces inflammation without major effect on LDL- or HDL-cholesterol.*


65. Mauer J, Chaurasia B, Goldau J, *et al.* Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated


d&dopt=Citation&list_uids=11395027.


78. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery


89. McInnes IB, Thompson L, Giles JT, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a


102. Serruys PW, Garc??a-Garc??a HM, Buszman P, et al. Effects of the direct


138. Zhao Z, Wu Y, Cheng M, et al. Activation of Th17/Th1 and Th1, but not Th17,


Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin-10 in


Table 1: Clinical trials targeting innate immune response

<table>
<thead>
<tr>
<th>Target</th>
<th>Drug</th>
<th>Clinical trial</th>
<th>Disease</th>
<th>N</th>
<th>Follow up</th>
<th>Dose</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL1</td>
<td>Anakinra</td>
<td>MRC-ILA Study (Phase II) [35]</td>
<td>Non-ST elevation ACS patients, with less than 48h with chest pain</td>
<td>182</td>
<td>1 year</td>
<td>10 mg daily 14 consecutive days</td>
<td>Reduce CRP first but then there is a rebound Increased CV accidents</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>14 consecutive days</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Canakinumab</td>
<td>Pilot Cantos [37]</td>
<td>Diabetes Mellitus at high CV risk</td>
<td>556</td>
<td>4 months</td>
<td>5, 15, 50 or 50 mg/month</td>
<td>Decreased hsCRP, IL6 and fibrinogen Slight increase triglycerides</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cantos (Phase III) [36]</td>
<td>Post-MI with persistent elevations of CRP (&gt;2 mg/L)</td>
<td>17,400</td>
<td>4 year</td>
<td>50, 150 or 300 mg or placebo every 3 months</td>
<td>Ongoing</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Colchicine</td>
<td>[40]</td>
<td>ACS</td>
<td>40</td>
<td>24 h</td>
<td>1mg followed by 0.5 mg 6-24 h before catheterization</td>
<td>Decrease transcoronary IL1β, IL18 and IL6 but not systemic levels</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>[39]</td>
<td></td>
<td>ACS or acute ischaemic stroke</td>
<td>80</td>
<td>30 days</td>
<td>1 mg/ day vs placebo</td>
<td>Did not decrease CRP</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>LoDoCo (Phase III) [41]</td>
<td>Stable CAD</td>
<td>Prior MI and either with, diabetes type 2 or metabolic syndrome</td>
<td>532</td>
<td>3 years</td>
<td>0.5 mg/day or placebo for 3 years</td>
<td>Positive with limitations (no blindo or placebo-controlled)</td>
</tr>
<tr>
<td></td>
<td>Unknown</td>
<td>Methotrexate [59]</td>
<td></td>
<td>7,000</td>
<td>3-5 years</td>
<td>15-20 mg/wk</td>
<td>Ongoing</td>
</tr>
<tr>
<td></td>
<td>Il6</td>
<td>Tocilizumab (Il6 Consortium) [81,82]</td>
<td>RA</td>
<td>139,449</td>
<td>4-8 weeks</td>
<td>4-8 mg/kg every 4 weeks</td>
<td>IL6R rs7529229 variant associated with reduced CRP and fibrinogen correlated with tocilizumab</td>
</tr>
<tr>
<td>Treatment</td>
<td>Study Name</td>
<td>Patient Details</td>
<td>Duration</td>
<td>Outcome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>------------</td>
<td>-----------------</td>
<td>----------</td>
<td>---------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MEASURE (Phase IV) [89]</td>
<td>In RA patients already treated with MTX</td>
<td>132</td>
<td>8 mg/kg</td>
<td>1 year</td>
<td>No effect on atherogenic small dense LDL. Increased in non-atherogenic LDL. Increase PON1. Decrease sPLA&lt;sub&gt;2&lt;/sub&gt; and amiloyd A.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Five core Phase III [90]</td>
<td>RA patients</td>
<td>4,199 controls 4,099 patients</td>
<td>8 mg/kg to 4 mg/kg depending on side effects</td>
<td>1-3 years</td>
<td>Decrease MI.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adalimumab (ADA9 vs Tocilizumab (TCZ))</td>
<td>MTX refractory RA patients</td>
<td>163 TCZ 162 ADA</td>
<td>8 mg/kg (TCZ) 40 mg ADA</td>
<td>6 years</td>
<td>Decrease CRP. Increase lipid levels.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lp-PLA&lt;sub&gt;2&lt;/sub&gt; Darapladib</td>
<td>in coronary patients</td>
<td>959</td>
<td>40, 80 or 160 mg/day for 12 weeks</td>
<td>12 weeks</td>
<td>Decrease Lp-PLA&lt;sub&gt;2&lt;/sub&gt;. Decrease IL6 and CRP.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IBIS-2(Phase II) [102]</td>
<td>angiographically proven CAD</td>
<td>300</td>
<td>160 mg or placebo 12 consecutive months</td>
<td>12 months</td>
<td>Decrease necrotic core expansion. Decrease Lp-PLA2 and no change in CRP.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STABILITY [103]</td>
<td>Stable CAD</td>
<td>15,828</td>
<td>160 mg/day or placebo</td>
<td>3.7 years</td>
<td>Failed in primary endpoints, did not decrease death due to MI, stroke or CV disease.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOLID-TIMI 52 [104]</td>
<td>ACS</td>
<td>13,026</td>
<td>160 mg/day</td>
<td>2.5 years</td>
<td>Failed in any primary or secondary endpoint.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sPLA2</td>
<td>Varespladib</td>
<td>PLASMA I (Phase II) [118]</td>
<td>Stable CAD</td>
<td>396</td>
<td>8 weeks</td>
<td>Decrease sPLA2-II, oxLDL, hsCRP, LDL size. Did not decrease LDL levels.</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
<td>--------------------------</td>
<td>------------</td>
<td>-----</td>
<td>---------</td>
<td>---------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PLASMA II (Phase II) [119]</td>
<td>Stable CAD</td>
<td>197</td>
<td>250 or 500 mg daily</td>
<td>8 weeks</td>
<td>Same as PLASMA I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FRANCIS [120]</td>
<td>96 hours of an ACS event</td>
<td>625</td>
<td>500mg</td>
<td>6 months</td>
<td>Decrease cholesterol, CRP and sPLAA2. No effect in primary endpoint</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VISTA-16 [121]</td>
<td>96 hours of an ACS event</td>
<td>5,000</td>
<td>500 mg</td>
<td>6 months</td>
<td>Increased MI rate</td>
</tr>
</tbody>
</table>